HRP20040659A2 - 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors - Google Patents

Info

Publication number

HRP20040659A2

HRP20040659A2 HR20040659A HRP20040659A HRP20040659A2 HR P20040659 A2 HRP20040659 A2 HR P20040659A2 HR 20040659 A HR20040659 A HR 20040659A HR P20040659 A HRP20040659 A HR P20040659A HR P20040659 A2 HRP20040659 A2 HR P20040659A2

Authority

HR

Croatia

Prior art keywords

preparation

optionally substituted

hydrogen

compound according

alkyl

Prior art date

2002-01-22

Links

• Espacenet
• Global Dossier
• Discuss

• 239000003112 inhibitor Substances 0.000 title description 37
• 150000001875 compounds Chemical class 0.000 claims description 368
• 238000002360 preparation method Methods 0.000 claims description 334
• 238000000034 method Methods 0.000 claims description 100
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 77
• 239000001257 hydrogen Substances 0.000 claims description 66
• 229910052739 hydrogen Inorganic materials 0.000 claims description 66
• 150000003839 salts Chemical class 0.000 claims description 46
• 238000011282 treatment Methods 0.000 claims description 46
• 125000001188 haloalkyl group Chemical group 0.000 claims description 39
• 125000005843 halogen group Chemical group 0.000 claims description 39
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 36
• 125000003118 aryl group Chemical group 0.000 claims description 36
• 239000012453 solvate Substances 0.000 claims description 28
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 27
• 125000000217 alkyl group Chemical group 0.000 claims description 27
• -1 aromatic heterocycle Chemical group 0.000 claims description 27
• 239000003814 drug Substances 0.000 claims description 22
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 22
• 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 20
• 125000000623 heterocyclic group Chemical group 0.000 claims description 16
• 229920006395 saturated elastomer Polymers 0.000 claims description 16
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
• 229910052760 oxygen Inorganic materials 0.000 claims description 15
• CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims description 15
• 201000001320 Atherosclerosis Diseases 0.000 claims description 14
• 230000003176 fibrotic effect Effects 0.000 claims description 14
• 125000005842 heteroatom Chemical group 0.000 claims description 14
• 229910052757 nitrogen Inorganic materials 0.000 claims description 14
• 229910052717 sulfur Inorganic materials 0.000 claims description 14
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
• 206010028980 Neoplasm Diseases 0.000 claims description 11
• 230000001732 thrombotic effect Effects 0.000 claims description 11
• 101800004538 Bradykinin Proteins 0.000 claims description 10
• QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims description 10
• QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims description 10
• 229940079593 drug Drugs 0.000 claims description 10
• 150000002431 hydrogen Chemical group 0.000 claims description 9
• 125000002883 imidazolyl group Chemical group 0.000 claims description 9
• 201000011510 cancer Diseases 0.000 claims description 8
• 208000027866 inflammatory disease Diseases 0.000 claims description 8
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 7
• 208000032544 Cicatrix Diseases 0.000 claims description 7
• 231100000241 scar Toxicity 0.000 claims description 7
• 230000037387 scars Effects 0.000 claims description 7
• 239000003153 chemical reaction reagent Substances 0.000 claims description 6
• LVCATUGNENEDGZ-ZDUSSCGKSA-N (2s)-2-(2-aminoethoxy)-3-(1-phenylimidazol-4-yl)propanoic acid Chemical compound C1=NC(C[C@H](OCCN)C(O)=O)=CN1C1=CC=CC=C1 LVCATUGNENEDGZ-ZDUSSCGKSA-N 0.000 claims description 5
• MAWYISWEMHTKMO-RISCZKNCSA-N (2s)-2-[(2r)-1-aminopropan-2-yl]oxy-3-(1-phenylimidazol-4-yl)propanoic acid Chemical compound C1=NC(C[C@H](O[C@@H](CN)C)C(O)=O)=CN1C1=CC=CC=C1 MAWYISWEMHTKMO-RISCZKNCSA-N 0.000 claims description 5
• RRBGXUCVOHIFHY-SVRRBLITSA-N (2s)-2-[(2r)-1-aminopropan-2-yl]oxy-3-(1h-imidazol-5-yl)propanoic acid Chemical compound NC[C@@H](C)O[C@H](C(O)=O)CC1=CNC=N1 RRBGXUCVOHIFHY-SVRRBLITSA-N 0.000 claims description 5
• 150000003951 lactams Chemical group 0.000 claims description 5
• LGGSGJJWBHFYEW-ZETCQYMHSA-N (2s)-2-(2-aminoethoxy)-3-(1h-imidazol-5-yl)propanoic acid Chemical compound NCCO[C@H](C(O)=O)CC1=CNC=N1 LGGSGJJWBHFYEW-ZETCQYMHSA-N 0.000 claims description 4
• KETHMDBAGCMVQJ-CJNGLKHVSA-N (2s)-2-[(2r)-1-aminopropan-2-yl]oxy-3-[1-(2-cyclohexylethyl)imidazol-4-yl]propanoic acid Chemical compound C1=NC(C[C@H](O[C@@H](CN)C)C(O)=O)=CN1CCC1CCCCC1 KETHMDBAGCMVQJ-CJNGLKHVSA-N 0.000 claims description 4
• SLRPONFABVFCPA-BBRMVZONSA-N (2s)-2-[(2s)-2-aminopropoxy]-3-[1-(2-cyclohexylethyl)imidazol-4-yl]propanoic acid Chemical compound C1=NC(C[C@H](OC[C@@H](N)C)C(O)=O)=CN1CCC1CCCCC1 SLRPONFABVFCPA-BBRMVZONSA-N 0.000 claims description 4
• 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 4
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 4
• 125000002947 alkylene group Chemical group 0.000 claims description 4
• 125000002837 carbocyclic group Chemical group 0.000 claims description 4
• 125000003367 polycyclic group Chemical group 0.000 claims description 4
• 125000001424 substituent group Chemical group 0.000 claims description 4
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
• QOJWERXDJOWTNM-PWSUYJOCSA-N (2s)-2-[(2r)-1-aminopropan-2-yl]oxy-3-(1-pyridin-2-ylimidazol-4-yl)propanoic acid Chemical compound C1=NC(C[C@H](O[C@@H](CN)C)C(O)=O)=CN1C1=CC=CC=N1 QOJWERXDJOWTNM-PWSUYJOCSA-N 0.000 claims description 2
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
• 238000012423 maintenance Methods 0.000 claims description 2
• 238000006467 substitution reaction Methods 0.000 claims description 2
• 102100035792 Kininogen-1 Human genes 0.000 claims 3
• 125000000753 cycloalkyl group Chemical group 0.000 claims 1
• 239000003937 drug carrier Substances 0.000 claims 1
• 239000000825 pharmaceutical preparation Substances 0.000 claims 1
• 238000000197 pyrolysis Methods 0.000 claims 1
• 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 claims 1
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 306
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 288
• 239000000203 mixture Substances 0.000 description 215
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 198
• 239000000243 solution Substances 0.000 description 194
• HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 192
• 238000005160 1H NMR spectroscopy Methods 0.000 description 145
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 132
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 122
• 229910001868 water Inorganic materials 0.000 description 114
• 230000002829 reductive effect Effects 0.000 description 110
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 91
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 75
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 72
• 229910021529 ammonia Inorganic materials 0.000 description 66
• 229940093499 ethyl acetate Drugs 0.000 description 66
• 235000019439 ethyl acetate Nutrition 0.000 description 66
• 238000010898 silica gel chromatography Methods 0.000 description 63
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 41
• OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 40
• VSEAAEQOQBMPQF-UHFFFAOYSA-N morpholin-3-one Chemical compound O=C1COCCN1 VSEAAEQOQBMPQF-UHFFFAOYSA-N 0.000 description 40
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 39
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 39
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 35
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 34
• 108090000201 Carboxypeptidase B2 Proteins 0.000 description 32
• 239000000741 silica gel Substances 0.000 description 32
• 229910002027 silica gel Inorganic materials 0.000 description 32
• OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 30
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 30
• 238000004587 chromatography analysis Methods 0.000 description 29
• 239000012043 crude product Substances 0.000 description 27
• 239000000047 product Substances 0.000 description 27
• 239000000651 prodrug Substances 0.000 description 26
• 229940002612 prodrug Drugs 0.000 description 26
• 102000003847 Carboxypeptidase B2 Human genes 0.000 description 25
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 24
• 239000003480 eluent Substances 0.000 description 24
• 239000007787 solid Substances 0.000 description 23
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
• PCCNIENXBRUYFK-UHFFFAOYSA-O azanium;cerium(4+);pentanitrate Chemical compound [NH4+].[Ce+4].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O PCCNIENXBRUYFK-UHFFFAOYSA-O 0.000 description 21
• 239000006260 foam Substances 0.000 description 21
• NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 20
• 238000010828 elution Methods 0.000 description 20
• 239000003456 ion exchange resin Substances 0.000 description 20
• 229920003303 ion-exchange polymer Polymers 0.000 description 20
• 239000010410 layer Substances 0.000 description 20
• 238000004452 microanalysis Methods 0.000 description 20
• PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 19
• 239000000706 filtrate Substances 0.000 description 19
• NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 19
• 102000009123 Fibrin Human genes 0.000 description 18
• 108010073385 Fibrin Proteins 0.000 description 18
• BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 18
• 229950003499 fibrin Drugs 0.000 description 18
• XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 18
• ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 18
• 208000007536 Thrombosis Diseases 0.000 description 17
• 229920001467 poly(styrenesulfonates) Polymers 0.000 description 17
• 238000004809 thin layer chromatography Methods 0.000 description 17
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 16
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 16
• 238000006243 chemical reaction Methods 0.000 description 16
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 15
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 15
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 15
• 201000010099 disease Diseases 0.000 description 15
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
• 239000002904 solvent Substances 0.000 description 15
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
• 230000015271 coagulation Effects 0.000 description 14
• 238000005345 coagulation Methods 0.000 description 14
• 239000000284 extract Substances 0.000 description 14
• 238000004458 analytical method Methods 0.000 description 13
• 230000015572 biosynthetic process Effects 0.000 description 13
• 230000020764 fibrinolysis Effects 0.000 description 13
• 230000005764 inhibitory process Effects 0.000 description 13
• 239000003921 oil Substances 0.000 description 13
• 235000019198 oils Nutrition 0.000 description 13
• 239000007858 starting material Substances 0.000 description 13
• 235000019502 Orange oil Nutrition 0.000 description 12
• 150000001336 alkenes Chemical class 0.000 description 12
• 239000010502 orange oil Substances 0.000 description 12
• 230000002265 prevention Effects 0.000 description 12
• 239000008346 aqueous phase Substances 0.000 description 11
• 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 11
• 239000011541 reaction mixture Substances 0.000 description 11
• YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 10
• IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 10
• 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 10
• 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 10
• 150000001299 aldehydes Chemical class 0.000 description 10
• 150000001413 amino acids Chemical class 0.000 description 10
• 239000003146 anticoagulant agent Substances 0.000 description 10
• 239000003054 catalyst Substances 0.000 description 10
• 239000003795 chemical substances by application Substances 0.000 description 10
• 239000012074 organic phase Substances 0.000 description 10
• ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 10
• 239000000725 suspension Substances 0.000 description 10
• 229960000187 tissue plasminogen activator Drugs 0.000 description 10
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
• KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 9
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
• 230000009089 cytolysis Effects 0.000 description 9
• 239000002480 mineral oil Substances 0.000 description 9
• 235000010446 mineral oil Nutrition 0.000 description 9
• 239000012071 phase Substances 0.000 description 9
• 239000012312 sodium hydride Substances 0.000 description 9
• 229910000104 sodium hydride Inorganic materials 0.000 description 9
• 239000000126 substance Substances 0.000 description 9
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 8
• 108010085169 Lysine carboxypeptidase Proteins 0.000 description 8
• 239000012359 Methanesulfonyl chloride Substances 0.000 description 8
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
• 208000006011 Stroke Diseases 0.000 description 8
• 239000002253 acid Substances 0.000 description 8
• 235000001014 amino acid Nutrition 0.000 description 8
• 239000012230 colorless oil Substances 0.000 description 8
• 238000004440 column chromatography Methods 0.000 description 8
• FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 8
• QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 8
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
• 238000010992 reflux Methods 0.000 description 8
• 229910000029 sodium carbonate Inorganic materials 0.000 description 8
• 238000001356 surgical procedure Methods 0.000 description 8
• 206010002383 Angina Pectoris Diseases 0.000 description 7
• 102400000967 Bradykinin Human genes 0.000 description 7
• 102100035023 Carboxypeptidase B2 Human genes 0.000 description 7
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 7
• 235000019270 ammonium chloride Nutrition 0.000 description 7
• 238000003556 assay Methods 0.000 description 7
• 239000008280 blood Substances 0.000 description 7
• 210000004369 blood Anatomy 0.000 description 7
• 239000012267 brine Substances 0.000 description 7
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 7
• 229910000024 caesium carbonate Inorganic materials 0.000 description 7
• OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 7
• 208000029078 coronary artery disease Diseases 0.000 description 7
• 208000010125 myocardial infarction Diseases 0.000 description 7
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 6
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
• WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 6
• 108090000190 Thrombin Proteins 0.000 description 6
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 6
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 6
• 229960004676 antithrombotic agent Drugs 0.000 description 6
• 230000017531 blood circulation Effects 0.000 description 6
• 239000006185 dispersion Substances 0.000 description 6
• 208000014674 injury Diseases 0.000 description 6
• KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 6
• 230000014759 maintenance of location Effects 0.000 description 6
• 239000012044 organic layer Substances 0.000 description 6
• 230000008569 process Effects 0.000 description 6
• 238000011477 surgical intervention Methods 0.000 description 6
• 208000011580 syndromic disease Diseases 0.000 description 6
• DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 6
• 230000009466 transformation Effects 0.000 description 6
• ZQEXIXXJFSQPNA-UHFFFAOYSA-N 1h-imidazole-5-carbaldehyde Chemical compound O=CC1=CNC=N1 ZQEXIXXJFSQPNA-UHFFFAOYSA-N 0.000 description 5
• VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 5
• 229920000858 Cyclodextrin Polymers 0.000 description 5
• 206010051055 Deep vein thrombosis Diseases 0.000 description 5
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
• 206010047249 Venous thrombosis Diseases 0.000 description 5
• 229960000583 acetic acid Drugs 0.000 description 5
• 235000011054 acetic acid Nutrition 0.000 description 5
• 150000007513 acids Chemical class 0.000 description 5
• 230000004913 activation Effects 0.000 description 5
• 150000001414 amino alcohols Chemical class 0.000 description 5
• 230000002785 anti-thrombosis Effects 0.000 description 5
• 239000002775 capsule Substances 0.000 description 5
• 239000003085 diluting agent Substances 0.000 description 5
• 239000000843 powder Substances 0.000 description 5
• 108090000765 processed proteins & peptides Proteins 0.000 description 5
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
• 235000017557 sodium bicarbonate Nutrition 0.000 description 5
• 239000011780 sodium chloride Substances 0.000 description 5
• 238000012360 testing method Methods 0.000 description 5
• 230000008733 trauma Effects 0.000 description 5
• JRQAAYVLPPGEHT-UHFFFAOYSA-N 2-bromoethylcyclohexane Chemical compound BrCCC1CCCCC1 JRQAAYVLPPGEHT-UHFFFAOYSA-N 0.000 description 4
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
• 108090000087 Carboxypeptidase B Proteins 0.000 description 4
• 102000003670 Carboxypeptidase B Human genes 0.000 description 4
• 102000005367 Carboxypeptidases Human genes 0.000 description 4
• 108010006303 Carboxypeptidases Proteins 0.000 description 4
• 108010010803 Gelatin Proteins 0.000 description 4
• 208000018262 Peripheral vascular disease Diseases 0.000 description 4
• 102000013566 Plasminogen Human genes 0.000 description 4
• 108010051456 Plasminogen Proteins 0.000 description 4
• 206010040047 Sepsis Diseases 0.000 description 4
• 229920002472 Starch Polymers 0.000 description 4
• 150000001412 amines Chemical class 0.000 description 4
• 206010003246 arthritis Diseases 0.000 description 4
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
• 230000007211 cardiovascular event Effects 0.000 description 4
• 230000035602 clotting Effects 0.000 description 4
• 230000008021 deposition Effects 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 238000010790 dilution Methods 0.000 description 4
• 239000012895 dilution Substances 0.000 description 4
• 238000004090 dissolution Methods 0.000 description 4
• 238000009472 formulation Methods 0.000 description 4
• 239000008273 gelatin Substances 0.000 description 4
• 229920000159 gelatin Polymers 0.000 description 4
• 235000019322 gelatine Nutrition 0.000 description 4
• 235000011852 gelatine desserts Nutrition 0.000 description 4
• 230000002401 inhibitory effect Effects 0.000 description 4
• 210000003734 kidney Anatomy 0.000 description 4
• 208000031225 myocardial ischemia Diseases 0.000 description 4
• 239000012299 nitrogen atmosphere Substances 0.000 description 4
• 230000003287 optical effect Effects 0.000 description 4
• 239000000546 pharmaceutical excipient Substances 0.000 description 4
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
• 239000002244 precipitate Substances 0.000 description 4
• 230000000019 pro-fibrinolytic effect Effects 0.000 description 4
• 125000006239 protecting group Chemical group 0.000 description 4
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
• 239000012321 sodium triacetoxyborohydride Substances 0.000 description 4
• 239000008107 starch Substances 0.000 description 4
• 235000019698 starch Nutrition 0.000 description 4
• 229940032147 starch Drugs 0.000 description 4
• 238000003756 stirring Methods 0.000 description 4
• 239000000758 substrate Substances 0.000 description 4
• 238000007892 surgical revascularization Methods 0.000 description 4
• 238000003786 synthesis reaction Methods 0.000 description 4
• 229940124597 therapeutic agent Drugs 0.000 description 4
• JKIGHOARKAIPJI-UHFFFAOYSA-N (3,4-dichlorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)C(Cl)=C1 JKIGHOARKAIPJI-UHFFFAOYSA-N 0.000 description 3
• CAYQIZIAYYNFCS-UHFFFAOYSA-N (4-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)C=C1 CAYQIZIAYYNFCS-UHFFFAOYSA-N 0.000 description 3
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
• 208000004476 Acute Coronary Syndrome Diseases 0.000 description 3
• 208000024827 Alzheimer disease Diseases 0.000 description 3
• 239000004475 Arginine Substances 0.000 description 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
• 229940121981 Carboxypeptidase inhibitor Drugs 0.000 description 3
• 101710127041 Carboxypeptidase inhibitor Proteins 0.000 description 3
• 206010008088 Cerebral artery embolism Diseases 0.000 description 3
• 206010008132 Cerebral thrombosis Diseases 0.000 description 3
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
• 206010012438 Dermatitis atopic Diseases 0.000 description 3
• 208000005189 Embolism Diseases 0.000 description 3
• 201000009273 Endometriosis Diseases 0.000 description 3
• 102000004190 Enzymes Human genes 0.000 description 3
• 108090000790 Enzymes Proteins 0.000 description 3
• 244000166102 Eucalyptus leucoxylon Species 0.000 description 3
• 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 3
• 239000007995 HEPES buffer Substances 0.000 description 3
• 208000032843 Hemorrhage Diseases 0.000 description 3
• 206010020772 Hypertension Diseases 0.000 description 3
• 206010061218 Inflammation Diseases 0.000 description 3
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
• 206010022489 Insulin Resistance Diseases 0.000 description 3
• 201000001429 Intracranial Thrombosis Diseases 0.000 description 3
• 208000019693 Lung disease Diseases 0.000 description 3
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
• 101710140999 Metallocarboxypeptidase inhibitor Proteins 0.000 description 3
• 208000018737 Parkinson disease Diseases 0.000 description 3
• 201000004681 Psoriasis Diseases 0.000 description 3
• 208000010378 Pulmonary Embolism Diseases 0.000 description 3
• 244000061456 Solanum tuberosum Species 0.000 description 3
• 235000002595 Solanum tuberosum Nutrition 0.000 description 3
• 238000009825 accumulation Methods 0.000 description 3
• 239000004480 active ingredient Substances 0.000 description 3
• 230000006978 adaptation Effects 0.000 description 3
• 239000002168 alkylating agent Substances 0.000 description 3
• 229940100198 alkylating agent Drugs 0.000 description 3
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
• 206010003119 arrhythmia Diseases 0.000 description 3
• 208000006673 asthma Diseases 0.000 description 3
• 201000008937 atopic dermatitis Diseases 0.000 description 3
• 230000000740 bleeding effect Effects 0.000 description 3
• 230000023555 blood coagulation Effects 0.000 description 3
• 125000005620 boronic acid group Chemical class 0.000 description 3
• 210000004899 c-terminal region Anatomy 0.000 description 3
• 206010008118 cerebral infarction Diseases 0.000 description 3
• 208000026106 cerebrovascular disease Diseases 0.000 description 3
• 239000000460 chlorine Substances 0.000 description 3
• 229910052801 chlorine Inorganic materials 0.000 description 3
• 238000000502 dialysis Methods 0.000 description 3
• 239000002552 dosage form Substances 0.000 description 3
• 230000000694 effects Effects 0.000 description 3
• 229940088598 enzyme Drugs 0.000 description 3
• 150000002148 esters Chemical class 0.000 description 3
• 208000008487 fibromuscular dysplasia Diseases 0.000 description 3
• 239000000945 filler Substances 0.000 description 3
• 125000000524 functional group Chemical group 0.000 description 3
• 239000000499 gel Substances 0.000 description 3
• 235000011187 glycerol Nutrition 0.000 description 3
• 210000002216 heart Anatomy 0.000 description 3
• 230000007062 hydrolysis Effects 0.000 description 3
• 238000006460 hydrolysis reaction Methods 0.000 description 3
• 230000004054 inflammatory process Effects 0.000 description 3
• 201000010849 intracranial embolism Diseases 0.000 description 3
• 230000000366 juvenile effect Effects 0.000 description 3
• 239000008101 lactose Substances 0.000 description 3
• JNODQFNWMXFMEV-UHFFFAOYSA-N latrepirdine Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1 JNODQFNWMXFMEV-UHFFFAOYSA-N 0.000 description 3
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
• 239000011777 magnesium Substances 0.000 description 3
• 229910052749 magnesium Inorganic materials 0.000 description 3
• 238000004949 mass spectrometry Methods 0.000 description 3
• 238000001819 mass spectrum Methods 0.000 description 3
• 239000011159 matrix material Substances 0.000 description 3
• 230000004770 neurodegeneration Effects 0.000 description 3
• 208000015122 neurodegenerative disease Diseases 0.000 description 3
• 239000002674 ointment Substances 0.000 description 3
• 239000003208 petroleum Substances 0.000 description 3
• UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 3
• 230000004044 response Effects 0.000 description 3
• 208000037803 restenosis Diseases 0.000 description 3
• 230000000717 retained effect Effects 0.000 description 3
• 239000007921 spray Substances 0.000 description 3
• 230000002459 sustained effect Effects 0.000 description 3
• 210000001519 tissue Anatomy 0.000 description 3
• RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 3
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
• 230000003966 vascular damage Effects 0.000 description 3
• KWPACVJPAFGBEQ-IKGGRYGDSA-N (2s)-1-[(2r)-2-amino-3-phenylpropanoyl]-n-[(3s)-1-chloro-6-(diaminomethylideneamino)-2-oxohexan-3-yl]pyrrolidine-2-carboxamide Chemical compound C([C@@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)CCl)C1=CC=CC=C1 KWPACVJPAFGBEQ-IKGGRYGDSA-N 0.000 description 2
• AHHSAESBCYZCJK-HNNXBMFYSA-N (2s)-2-(1h-imidazol-5-ylmethyl)-4-[(4-methoxyphenyl)methyl]morpholin-3-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)[C@H](CC=2N=CNC=2)OCC1 AHHSAESBCYZCJK-HNNXBMFYSA-N 0.000 description 2
• BZUABSYGNBFITP-DDOQPMFUSA-N (2s)-6-amino-2-[[(2s)-2-[[(e)-3-(furan-2-yl)prop-2-enoyl]amino]propanoyl]amino]hexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)\C=C\C1=CC=CO1 BZUABSYGNBFITP-DDOQPMFUSA-N 0.000 description 2
• LOPQWMNOCSRRSR-UHFFFAOYSA-N (3-phenoxyphenyl)boronic acid Chemical compound OB(O)C1=CC=CC(OC=2C=CC=CC=2)=C1 LOPQWMNOCSRRSR-UHFFFAOYSA-N 0.000 description 2
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
• VKVCLXDFOQQABP-UHFFFAOYSA-N 2-[2-(diaminomethylideneamino)ethylsulfanyl]butanedioic acid Chemical compound NC(N)=NCCSC(C(O)=O)CC(O)=O VKVCLXDFOQQABP-UHFFFAOYSA-N 0.000 description 2
• VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
• KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
• VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical class [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 2
• 201000003883 Cystic fibrosis Diseases 0.000 description 2
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
• 102000010911 Enzyme Precursors Human genes 0.000 description 2
• 108010062466 Enzyme Precursors Proteins 0.000 description 2
• 108010049003 Fibrinogen Proteins 0.000 description 2
• 102000008946 Fibrinogen Human genes 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
• 239000004472 Lysine Substances 0.000 description 2
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
• MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
• 238000005481 NMR spectroscopy Methods 0.000 description 2
• 239000007832 Na2SO4 Substances 0.000 description 2
• 208000008589 Obesity Diseases 0.000 description 2
• 206010053159 Organ failure Diseases 0.000 description 2
• 208000002193 Pain Diseases 0.000 description 2
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
• 102100026966 Thrombomodulin Human genes 0.000 description 2
• 108010079274 Thrombomodulin Proteins 0.000 description 2
• 208000031737 Tissue Adhesions Diseases 0.000 description 2
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
• 230000002159 abnormal effect Effects 0.000 description 2
• 238000002835 absorbance Methods 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 239000000443 aerosol Substances 0.000 description 2
• 238000005804 alkylation reaction Methods 0.000 description 2
• 125000004429 atom Chemical group 0.000 description 2
• 210000004204 blood vessel Anatomy 0.000 description 2
• ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
• 229910052794 bromium Inorganic materials 0.000 description 2
• 125000001246 bromo group Chemical group Br* 0.000 description 2
• 230000015556 catabolic process Effects 0.000 description 2
• 239000007810 chemical reaction solvent Substances 0.000 description 2
• 125000001309 chloro group Chemical group Cl* 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 239000011248 coating agent Substances 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 230000002860 competitive effect Effects 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• BERDEBHAJNAUOM-UHFFFAOYSA-N copper(i) oxide Chemical compound [Cu]O[Cu] BERDEBHAJNAUOM-UHFFFAOYSA-N 0.000 description 2
• 238000007887 coronary angioplasty Methods 0.000 description 2
• 239000006071 cream Substances 0.000 description 2
• 238000010908 decantation Methods 0.000 description 2
• 238000010511 deprotection reaction Methods 0.000 description 2
• ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
• 229940012952 fibrinogen Drugs 0.000 description 2
• 210000002950 fibroblast Anatomy 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 238000001640 fractional crystallisation Methods 0.000 description 2
• 108010039140 furylacryloylalanyllysine Proteins 0.000 description 2
• 239000011521 glass Substances 0.000 description 2
• 238000004128 high performance liquid chromatography Methods 0.000 description 2
• 238000005984 hydrogenation reaction Methods 0.000 description 2
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
• 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
• 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• 229940030980 inova Drugs 0.000 description 2
• 230000002452 interceptive effect Effects 0.000 description 2
• 229910052740 iodine Inorganic materials 0.000 description 2
• 238000005342 ion exchange Methods 0.000 description 2
• 230000000302 ischemic effect Effects 0.000 description 2
• 229960004592 isopropanol Drugs 0.000 description 2
• 150000002576 ketones Chemical class 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• 229910052744 lithium Inorganic materials 0.000 description 2
• 230000007774 longterm Effects 0.000 description 2
• 239000006210 lotion Substances 0.000 description 2
• 239000000314 lubricant Substances 0.000 description 2
• 210000004072 lung Anatomy 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 238000002844 melting Methods 0.000 description 2
• 230000008018 melting Effects 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• 229940098779 methanesulfonic acid Drugs 0.000 description 2
• XHXVAJHZTIXQQD-UHFFFAOYSA-N n-[bis(aziridin-1-yl)phosphoryl]-5-[(4-butoxyphenyl)methyl]-2,6-dimethylpyrimidin-4-amine Chemical compound C1=CC(OCCCC)=CC=C1CC1=C(C)N=C(C)N=C1NP(=O)(N1CC1)N1CC1 XHXVAJHZTIXQQD-UHFFFAOYSA-N 0.000 description 2
• 125000001624 naphthyl group Chemical group 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 235000020824 obesity Nutrition 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 230000001575 pathological effect Effects 0.000 description 2
• HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
• 229940012957 plasmin Drugs 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
• 229920000053 polysorbate 80 Polymers 0.000 description 2
• 229910000027 potassium carbonate Inorganic materials 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 239000003805 procoagulant Substances 0.000 description 2
• 230000001737 promoting effect Effects 0.000 description 2
• 230000002685 pulmonary effect Effects 0.000 description 2
• 230000008439 repair process Effects 0.000 description 2
• HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
• 229910052938 sodium sulfate Inorganic materials 0.000 description 2
• 235000011152 sodium sulphate Nutrition 0.000 description 2
• BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 2
• HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
• 229960004072 thrombin Drugs 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 230000007704 transition Effects 0.000 description 2
• 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 2
• KTOJGSDLJNUAEP-UHFFFAOYSA-N (2,5-difluorophenyl)boronic acid Chemical compound OB(O)C1=CC(F)=CC=C1F KTOJGSDLJNUAEP-UHFFFAOYSA-N 0.000 description 1
• NSJVYHOPHZMZPN-UHFFFAOYSA-N (2-methylphenyl)boronic acid Chemical compound CC1=CC=CC=C1B(O)O NSJVYHOPHZMZPN-UHFFFAOYSA-N 0.000 description 1
• HXKKHQJGJAFBHI-GSVOUGTGSA-N (2R)-1-aminopropan-2-ol Chemical compound C[C@@H](O)CN HXKKHQJGJAFBHI-GSVOUGTGSA-N 0.000 description 1
• BASAHWQUEPWGSA-SECBINFHSA-N (2r)-1-[(4-methoxyphenyl)methylamino]propan-2-ol Chemical compound COC1=CC=C(CNC[C@@H](C)O)C=C1 BASAHWQUEPWGSA-SECBINFHSA-N 0.000 description 1
• ITHXTSANOXLYDY-RXMQYKEDSA-N (2r)-2-[(2-bromoacetyl)amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(N)=NCCC[C@H](C(O)=O)NC(=O)CBr ITHXTSANOXLYDY-RXMQYKEDSA-N 0.000 description 1
• RRBGXUCVOHIFHY-HTRCEHHLSA-N (2r)-2-[(2r)-1-aminopropan-2-yl]oxy-3-(1h-imidazol-5-yl)propanoic acid Chemical compound NC[C@@H](C)O[C@@H](C(O)=O)CC1=CNC=N1 RRBGXUCVOHIFHY-HTRCEHHLSA-N 0.000 description 1
• JECRNIMUUGOGMJ-SECBINFHSA-N (2r)-2-[(4-methoxyphenyl)methylamino]propan-1-ol Chemical compound COC1=CC=C(CN[C@H](C)CO)C=C1 JECRNIMUUGOGMJ-SECBINFHSA-N 0.000 description 1
• BKMMTJMQCTUHRP-GSVOUGTGSA-N (2r)-2-aminopropan-1-ol Chemical compound C[C@@H](N)CO BKMMTJMQCTUHRP-GSVOUGTGSA-N 0.000 description 1
• FWZKFVSPBVYQRP-MLGOLLRUSA-N (2r,5r)-2-(1h-imidazol-5-ylmethyl)-4-[(4-methoxyphenyl)methyl]-5-methylmorpholin-3-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)[C@@H](CC=2N=CNC=2)OC[C@H]1C FWZKFVSPBVYQRP-MLGOLLRUSA-N 0.000 description 1
• QLMBEPADAHRBNJ-NTKDMRAZSA-N (2r,5r)-2-[[1-(2-cyclohexylethyl)imidazol-4-yl]methyl]-4-[(4-methoxyphenyl)methyl]-5-methylmorpholin-3-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)[C@@H](CC=2N=CN(CCC3CCCCC3)C=2)OC[C@H]1C QLMBEPADAHRBNJ-NTKDMRAZSA-N 0.000 description 1
• PHHNEKZFGGHEBH-CZUORRHYSA-N (2r,5r)-2-[[1-(2-cyclohexylethyl)imidazol-4-yl]methyl]-5-methylmorpholin-3-one Chemical compound O=C1N[C@H](C)CO[C@@H]1CC(N=C1)=CN1CCC1CCCCC1 PHHNEKZFGGHEBH-CZUORRHYSA-N 0.000 description 1
• JOWAZFKTCCDAHS-MLGOLLRUSA-N (2r,6r)-2-(1h-imidazol-5-ylmethyl)-4-[(4-methoxyphenyl)methyl]-6-methylmorpholin-3-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)[C@@H](CC=2N=CNC=2)O[C@H](C)C1 JOWAZFKTCCDAHS-MLGOLLRUSA-N 0.000 description 1
• WWZJFECTLNRCMG-HTRCEHHLSA-N (2r,6r)-2-(1h-imidazol-5-ylmethyl)-6-methylmorpholin-3-one Chemical compound O1[C@H](C)CNC(=O)[C@H]1CC1=CNC=N1 WWZJFECTLNRCMG-HTRCEHHLSA-N 0.000 description 1
• JOWAZFKTCCDAHS-BLLLJJGKSA-N (2r,6s)-2-(1h-imidazol-5-ylmethyl)-4-[(4-methoxyphenyl)methyl]-6-methylmorpholin-3-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)[C@@H](CC=2N=CNC=2)O[C@@H](C)C1 JOWAZFKTCCDAHS-BLLLJJGKSA-N 0.000 description 1
• TYMQRRRBZPASCH-YADARESESA-N (2r,6s)-2-[[1-(2-cyclohexylethyl)imidazol-4-yl]methyl]-4-[(4-methoxyphenyl)methyl]-6-methylmorpholin-3-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)[C@@H](CC=2N=CN(CCC3CCCCC3)C=2)O[C@@H](C)C1 TYMQRRRBZPASCH-YADARESESA-N 0.000 description 1
• QWPIXBXLBXUQCA-XJKSGUPXSA-N (2r,6s)-2-[[1-(2-cyclohexylethyl)imidazol-4-yl]methyl]-6-methylmorpholin-3-one Chemical compound O1[C@@H](C)CNC(=O)[C@H]1CC(N=C1)=CN1CCC1CCCCC1 QWPIXBXLBXUQCA-XJKSGUPXSA-N 0.000 description 1
• BASAHWQUEPWGSA-VIFPVBQESA-N (2s)-1-[(4-methoxyphenyl)methylamino]propan-2-ol Chemical compound COC1=CC=C(CNC[C@H](C)O)C=C1 BASAHWQUEPWGSA-VIFPVBQESA-N 0.000 description 1
• HXKKHQJGJAFBHI-VKHMYHEASA-N (2s)-1-aminopropan-2-ol Chemical compound C[C@H](O)CN HXKKHQJGJAFBHI-VKHMYHEASA-N 0.000 description 1
• YPTIWTFDKDJHQY-ZETCQYMHSA-N (2s)-2-(1h-imidazol-5-ylmethyl)morpholin-3-one Chemical compound O=C1NCCO[C@H]1CC1=CNC=N1 YPTIWTFDKDJHQY-ZETCQYMHSA-N 0.000 description 1
• JAMWMFGAEKLEEJ-JTQLQIEISA-N (2s)-2-(2-aminoethoxy)-3-(1-propylimidazol-4-yl)propanoic acid Chemical compound CCCN1C=NC(C[C@H](OCCN)C(O)=O)=C1 JAMWMFGAEKLEEJ-JTQLQIEISA-N 0.000 description 1
• MGQIYOQKVVJLOQ-KLXURFKVSA-N (2s)-2-(2-aminoethoxy)-3-(1h-imidazol-5-yl)propanoic acid;dihydrochloride Chemical compound Cl.Cl.NCCO[C@H](C(O)=O)CC1=CNC=N1 MGQIYOQKVVJLOQ-KLXURFKVSA-N 0.000 description 1
• VAABNDTVXFVLFU-HNNXBMFYSA-N (2s)-2-(2-aminoethoxy)-3-[1-(2-cyclohexylethyl)imidazol-4-yl]propanoic acid Chemical compound C1=NC(C[C@H](OCCN)C(O)=O)=CN1CCC1CCCCC1 VAABNDTVXFVLFU-HNNXBMFYSA-N 0.000 description 1
• VZWMKNSUQMUWJM-SQKCAUCHSA-N (2s)-2-(2-aminoethoxy)-3-[1-(4-tert-butylphenyl)imidazol-4-yl]propanoic acid;dihydrochloride Chemical compound Cl.Cl.C1=CC(C(C)(C)C)=CC=C1N1C=C(C[C@H](OCCN)C(O)=O)N=C1 VZWMKNSUQMUWJM-SQKCAUCHSA-N 0.000 description 1
• YSWQIVFTMWJNRL-ZDUSSCGKSA-N (2s)-2-(2-aminoethoxy)-3-[1-[3,5-bis(trifluoromethyl)phenyl]imidazol-4-yl]propanoic acid Chemical compound C1=NC(C[C@H](OCCN)C(O)=O)=CN1C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 YSWQIVFTMWJNRL-ZDUSSCGKSA-N 0.000 description 1
• WDNXRQVMRIUISP-ZDUSSCGKSA-N (2s)-2-[(1-phenylimidazol-4-yl)methyl]morpholin-3-one Chemical compound O=C1NCCO[C@H]1CC1=CN(C=2C=CC=CC=2)C=N1 WDNXRQVMRIUISP-ZDUSSCGKSA-N 0.000 description 1
• WAFODYZPNSCVJG-JTQLQIEISA-N (2s)-2-[(1-propylimidazol-4-yl)methyl]morpholin-3-one Chemical compound CCCN1C=NC(C[C@H]2C(NCCO2)=O)=C1 WAFODYZPNSCVJG-JTQLQIEISA-N 0.000 description 1
• RBHSULHXFWCENF-KOLCDFICSA-N (2s)-2-[(2r)-1-aminopropan-2-yl]oxy-3-(1-propylimidazol-4-yl)propanoic acid Chemical compound CCCN1C=NC(C[C@H](O[C@H](C)CN)C(O)=O)=C1 RBHSULHXFWCENF-KOLCDFICSA-N 0.000 description 1
• COVRYSTWTFAUHV-BOTBFRDUSA-N (2s)-2-[(2r)-1-aminopropan-2-yl]oxy-3-(1-pyridin-2-ylimidazol-4-yl)propanoic acid;dihydrochloride Chemical compound Cl.Cl.C1=NC(C[C@H](O[C@@H](CN)C)C(O)=O)=CN1C1=CC=CC=N1 COVRYSTWTFAUHV-BOTBFRDUSA-N 0.000 description 1
• IFUGVNMOKPRNBM-QRWLVFNGSA-N (2s)-2-[(2r)-1-aminopropan-2-yl]oxy-3-[1-(4-phenoxyphenyl)imidazol-4-yl]propanoic acid Chemical compound C1=NC(C[C@H](O[C@@H](CN)C)C(O)=O)=CN1C(C=C1)=CC=C1OC1=CC=CC=C1 IFUGVNMOKPRNBM-QRWLVFNGSA-N 0.000 description 1
• JUXZVVXTKINCQN-XCLFUZPHSA-N (2s)-2-[(2r)-1-aminopropan-2-yl]oxy-3-[1-[3-(3,4-dichlorophenyl)phenyl]imidazol-4-yl]propanoic acid Chemical compound C1=NC(C[C@H](O[C@@H](CN)C)C(O)=O)=CN1C1=CC=CC(C=2C=C(Cl)C(Cl)=CC=2)=C1 JUXZVVXTKINCQN-XCLFUZPHSA-N 0.000 description 1
• JECRNIMUUGOGMJ-VIFPVBQESA-N (2s)-2-[(4-methoxyphenyl)methylamino]propan-1-ol Chemical compound COC1=CC=C(CN[C@@H](C)CO)C=C1 JECRNIMUUGOGMJ-VIFPVBQESA-N 0.000 description 1
• JNWBYAZWNZUINP-QHCPKHFHSA-N (2s)-2-[[1-(2-cyclohexylethyl)imidazol-4-yl]methyl]-4-[(4-methoxyphenyl)methyl]morpholin-3-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)[C@H](CC=2N=CN(CCC3CCCCC3)C=2)OCC1 JNWBYAZWNZUINP-QHCPKHFHSA-N 0.000 description 1
• HYTHQFHZAAMXAV-HNNXBMFYSA-N (2s)-2-[[1-(2-cyclohexylethyl)imidazol-4-yl]methyl]morpholin-3-one Chemical compound O=C1NCCO[C@H]1CC(N=C1)=CN1CCC1CCCCC1 HYTHQFHZAAMXAV-HNNXBMFYSA-N 0.000 description 1
• JUHKHCZDOLKUSX-INIZCTEOSA-N (2s)-2-[[1-(4-tert-butylphenyl)imidazol-4-yl]methyl]morpholin-3-one Chemical compound C1=CC(C(C)(C)C)=CC=C1N1C=C(C[C@H]2C(NCCO2)=O)N=C1 JUHKHCZDOLKUSX-INIZCTEOSA-N 0.000 description 1
• OZZKREHPGYONAR-SFHVURJKSA-N (2s)-4-[(4-methoxyphenyl)methyl]-2-[(1-propylimidazol-4-yl)methyl]morpholin-3-one Chemical compound CCCN1C=NC(C[C@H]2C(N(CC=3C=CC(OC)=CC=3)CCO2)=O)=C1 OZZKREHPGYONAR-SFHVURJKSA-N 0.000 description 1
• FWZKFVSPBVYQRP-LRDDRELGSA-N (2s,5s)-2-(1h-imidazol-5-ylmethyl)-4-[(4-methoxyphenyl)methyl]-5-methylmorpholin-3-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)[C@H](CC=2N=CNC=2)OC[C@@H]1C FWZKFVSPBVYQRP-LRDDRELGSA-N 0.000 description 1
• QLMBEPADAHRBNJ-CYFREDJKSA-N (2s,5s)-2-[[1-(2-cyclohexylethyl)imidazol-4-yl]methyl]-4-[(4-methoxyphenyl)methyl]-5-methylmorpholin-3-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)[C@H](CC=2N=CN(CCC3CCCCC3)C=2)OC[C@@H]1C QLMBEPADAHRBNJ-CYFREDJKSA-N 0.000 description 1
• PHHNEKZFGGHEBH-BBRMVZONSA-N (2s,5s)-2-[[1-(2-cyclohexylethyl)imidazol-4-yl]methyl]-5-methylmorpholin-3-one Chemical compound O=C1N[C@@H](C)CO[C@H]1CC(N=C1)=CN1CCC1CCCCC1 PHHNEKZFGGHEBH-BBRMVZONSA-N 0.000 description 1
• JOWAZFKTCCDAHS-WBMJQRKESA-N (2s,6r)-2-(1h-imidazol-5-ylmethyl)-4-[(4-methoxyphenyl)methyl]-6-methylmorpholin-3-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)[C@H](CC=2N=CNC=2)O[C@H](C)C1 JOWAZFKTCCDAHS-WBMJQRKESA-N 0.000 description 1
• WWZJFECTLNRCMG-SVRRBLITSA-N (2s,6r)-2-(1h-imidazol-5-ylmethyl)-6-methylmorpholin-3-one Chemical compound O1[C@H](C)CNC(=O)[C@@H]1CC1=CNC=N1 WWZJFECTLNRCMG-SVRRBLITSA-N 0.000 description 1
• TYMQRRRBZPASCH-DVECYGJZSA-N (2s,6r)-2-[[1-(2-cyclohexylethyl)imidazol-4-yl]methyl]-4-[(4-methoxyphenyl)methyl]-6-methylmorpholin-3-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)[C@H](CC=2N=CN(CCC3CCCCC3)C=2)O[C@H](C)C1 TYMQRRRBZPASCH-DVECYGJZSA-N 0.000 description 1
• QWPIXBXLBXUQCA-CJNGLKHVSA-N (2s,6r)-2-[[1-(2-cyclohexylethyl)imidazol-4-yl]methyl]-6-methylmorpholin-3-one Chemical compound O1[C@H](C)CNC(=O)[C@@H]1CC(N=C1)=CN1CCC1CCCCC1 QWPIXBXLBXUQCA-CJNGLKHVSA-N 0.000 description 1
• GZZGBIHUBRASOP-RLWLMLJZSA-N (2s,6r)-2-[[1-(3-cyclohexyl-3-methylbutyl)imidazol-4-yl]methyl]-4-[(4-methoxyphenyl)methyl]-6-methylmorpholin-3-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)[C@H](CC=2N=CN(CCC(C)(C)C3CCCCC3)C=2)O[C@H](C)C1 GZZGBIHUBRASOP-RLWLMLJZSA-N 0.000 description 1
• UICRJSSZFBATCR-QAPCUYQASA-N (2s,6r)-2-[[1-(3-cyclohexyl-3-methylbutyl)imidazol-4-yl]methyl]-6-methylmorpholin-3-one Chemical compound O1[C@H](C)CNC(=O)[C@@H]1CC(N=C1)=CN1CCC(C)(C)C1CCCCC1 UICRJSSZFBATCR-QAPCUYQASA-N 0.000 description 1
• ZNPKKGHRXBHBBD-PIKZIKFNSA-N (2s,6r)-2-[[1-(4-cyclohexylphenyl)imidazol-4-yl]methyl]-4-[(4-methoxyphenyl)methyl]-6-methylmorpholin-3-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)[C@H](CC=2N=CN(C=2)C=2C=CC(=CC=2)C2CCCCC2)O[C@H](C)C1 ZNPKKGHRXBHBBD-PIKZIKFNSA-N 0.000 description 1
• RWCNCFSUCWISEN-PBHICJAKSA-N (2s,6r)-2-[[1-[2-(4,4-dimethylcyclohexyl)ethyl]imidazol-4-yl]methyl]-6-methylmorpholin-3-one Chemical compound O1[C@H](C)CNC(=O)[C@@H]1CC(N=C1)=CN1CCC1CCC(C)(C)CC1 RWCNCFSUCWISEN-PBHICJAKSA-N 0.000 description 1
• QNERLOLWHJDBDC-NGOKVRLYSA-N (2s,6r)-2-[[1-[3-(3-chlorophenyl)phenyl]imidazol-4-yl]methyl]-4-[(4-methoxyphenyl)methyl]-6-methylmorpholin-3-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)[C@H](CC=2N=CN(C=2)C=2C=C(C=CC=2)C=2C=C(Cl)C=CC=2)O[C@H](C)C1 QNERLOLWHJDBDC-NGOKVRLYSA-N 0.000 description 1
• QXBUODZKTIJTEB-UZLBHIALSA-N (2s,6r)-4-[(4-methoxyphenyl)methyl]-6-methyl-2-[(1-pyridin-2-ylimidazol-4-yl)methyl]morpholin-3-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)[C@H](CC=2N=CN(C=2)C=2N=CC=CC=2)O[C@H](C)C1 QXBUODZKTIJTEB-UZLBHIALSA-N 0.000 description 1
• ITTRLGIDSUTOFC-KOLCDFICSA-N (2s,6r)-6-methyl-2-[(1-propylimidazol-4-yl)methyl]morpholin-3-one Chemical compound CCCN1C=NC(C[C@H]2C(NC[C@@H](C)O2)=O)=C1 ITTRLGIDSUTOFC-KOLCDFICSA-N 0.000 description 1
• ATQIDPHNMDXFOD-PWSUYJOCSA-N (2s,6r)-6-methyl-2-[(1-pyridin-2-ylimidazol-4-yl)methyl]morpholin-3-one Chemical compound O1[C@H](C)CNC(=O)[C@@H]1CC1=CN(C=2N=CC=CC=2)C=N1 ATQIDPHNMDXFOD-PWSUYJOCSA-N 0.000 description 1
• SDEAGACSNFSZCU-UHFFFAOYSA-N (3-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(Cl)=C1 SDEAGACSNFSZCU-UHFFFAOYSA-N 0.000 description 1
• YEHSGKBGLGQJSM-UHFFFAOYSA-N (4-bromo-2-methylbutan-2-yl)cyclohexane Chemical compound BrCCC(C)(C)C1CCCCC1 YEHSGKBGLGQJSM-UHFFFAOYSA-N 0.000 description 1
• QBLFZIBJXUQVRF-UHFFFAOYSA-N (4-bromophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Br)C=C1 QBLFZIBJXUQVRF-UHFFFAOYSA-N 0.000 description 1
• LRWBGLILWSKAMP-UHFFFAOYSA-N (4-cyclohexyloxyphenyl)boronic acid Chemical compound C1=CC(B(O)O)=CC=C1OC1CCCCC1 LRWBGLILWSKAMP-UHFFFAOYSA-N 0.000 description 1
• KNQVRFYNQWNYPU-UHFFFAOYSA-N (4-cyclohexylphenyl)boronic acid Chemical compound C1=CC(B(O)O)=CC=C1C1CCCCC1 KNQVRFYNQWNYPU-UHFFFAOYSA-N 0.000 description 1
• RZCPLOMUUCFPQA-UHFFFAOYSA-N (4-ethylphenyl)boronic acid Chemical compound CCC1=CC=C(B(O)O)C=C1 RZCPLOMUUCFPQA-UHFFFAOYSA-N 0.000 description 1
• BIWQNIMLAISTBV-UHFFFAOYSA-N (4-methylphenyl)boronic acid Chemical compound CC1=CC=C(B(O)O)C=C1 BIWQNIMLAISTBV-UHFFFAOYSA-N 0.000 description 1
• XPEIJWZLPWNNOK-UHFFFAOYSA-N (4-phenylphenyl)boronic acid Chemical compound C1=CC(B(O)O)=CC=C1C1=CC=CC=C1 XPEIJWZLPWNNOK-UHFFFAOYSA-N 0.000 description 1
• NZHVIDXJYMPIAB-YVWDGHEZSA-N (5r)-2-[hydroxy-(1-tritylimidazol-4-yl)methyl]-4-[(4-methoxyphenyl)methyl]-5-methylmorpholin-3-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)C(C(O)C=2N=CN(C=2)C(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)OC[C@H]1C NZHVIDXJYMPIAB-YVWDGHEZSA-N 0.000 description 1
• DKWBWSBGQRMACC-HHHXNRCGSA-N (5r)-4-[(4-methoxyphenyl)methyl]-5-methyl-2-[(1-tritylimidazol-4-yl)methylidene]morpholin-3-one Chemical compound C1=CC(OC)=CC=C1CN([C@H](C)CO1)C(=O)C1=CC1=CN(C(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)C=N1 DKWBWSBGQRMACC-HHHXNRCGSA-N 0.000 description 1
• DCCPSNCYDOCXEW-SNVBAGLBSA-N (5r)-4-[(4-methoxyphenyl)methyl]-5-methylmorpholin-3-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)COC[C@H]1C DCCPSNCYDOCXEW-SNVBAGLBSA-N 0.000 description 1
• NZHVIDXJYMPIAB-SAFIJQOBSA-N (5s)-2-[hydroxy-(1-tritylimidazol-4-yl)methyl]-4-[(4-methoxyphenyl)methyl]-5-methylmorpholin-3-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)C(C(O)C=2N=CN(C=2)C(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)OC[C@@H]1C NZHVIDXJYMPIAB-SAFIJQOBSA-N 0.000 description 1
• DKWBWSBGQRMACC-MHZLTWQESA-N (5s)-4-[(4-methoxyphenyl)methyl]-5-methyl-2-[(1-tritylimidazol-4-yl)methylidene]morpholin-3-one Chemical compound C1=CC(OC)=CC=C1CN([C@@H](C)CO1)C(=O)C1=CC1=CN(C(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)C=N1 DKWBWSBGQRMACC-MHZLTWQESA-N 0.000 description 1
• DCCPSNCYDOCXEW-JTQLQIEISA-N (5s)-4-[(4-methoxyphenyl)methyl]-5-methylmorpholin-3-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)COC[C@@H]1C DCCPSNCYDOCXEW-JTQLQIEISA-N 0.000 description 1
• CUWPAWWWXIVWIG-GFCCVEGCSA-N (6r)-2-(1h-imidazol-5-ylmethylidene)-4-[(4-methoxyphenyl)methyl]-6-methylmorpholin-3-one Chemical compound C1=CC(OC)=CC=C1CN(C[C@@H](C)O1)C(=O)C1=CC1=CNC=N1 CUWPAWWWXIVWIG-GFCCVEGCSA-N 0.000 description 1
• XKUQPLAWPCJWGF-FTXHTYHOSA-N (6r)-2-[hydroxy-(1-propylimidazol-4-yl)methyl]-4-[(4-methoxyphenyl)methyl]-6-methylmorpholin-3-one Chemical compound CCCN1C=NC(C(O)C2C(N(CC=3C=CC(OC)=CC=3)C[C@@H](C)O2)=O)=C1 XKUQPLAWPCJWGF-FTXHTYHOSA-N 0.000 description 1
• ILIUIQIONQINOQ-YVWDGHEZSA-N (6r)-2-[hydroxy-(1-tritylimidazol-4-yl)methyl]-4-[(4-methoxyphenyl)methyl]-6-methylmorpholin-3-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)C(C(O)C=2N=CN(C=2)C(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)O[C@H](C)C1 ILIUIQIONQINOQ-YVWDGHEZSA-N 0.000 description 1
• NYIADCXSCUJUAU-OAHLLOKOSA-N (6r)-4-[(4-methoxyphenyl)methyl]-6-methyl-2-[(1-propylimidazol-4-yl)methylidene]morpholin-3-one Chemical compound CCCN1C=NC(C=C2C(N(CC=3C=CC(OC)=CC=3)C[C@@H](C)O2)=O)=C1 NYIADCXSCUJUAU-OAHLLOKOSA-N 0.000 description 1
• RIXGYXRSHYBWDU-HHHXNRCGSA-N (6r)-4-[(4-methoxyphenyl)methyl]-6-methyl-2-[(1-tritylimidazol-4-yl)methylidene]morpholin-3-one Chemical compound C1=CC(OC)=CC=C1CN(C[C@@H](C)O1)C(=O)C1=CC1=CN(C(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)C=N1 RIXGYXRSHYBWDU-HHHXNRCGSA-N 0.000 description 1
• FZPXRPMJRKWKNF-SNVBAGLBSA-N (6r)-4-[(4-methoxyphenyl)methyl]-6-methylmorpholin-3-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)CO[C@H](C)C1 FZPXRPMJRKWKNF-SNVBAGLBSA-N 0.000 description 1
• ILIUIQIONQINOQ-SAFIJQOBSA-N (6s)-2-[hydroxy-(1-tritylimidazol-4-yl)methyl]-4-[(4-methoxyphenyl)methyl]-6-methylmorpholin-3-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)C(C(O)C=2N=CN(C=2)C(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)O[C@@H](C)C1 ILIUIQIONQINOQ-SAFIJQOBSA-N 0.000 description 1
• RIXGYXRSHYBWDU-MHZLTWQESA-N (6s)-4-[(4-methoxyphenyl)methyl]-6-methyl-2-[(1-tritylimidazol-4-yl)methylidene]morpholin-3-one Chemical compound C1=CC(OC)=CC=C1CN(C[C@H](C)O1)C(=O)C1=CC1=CN(C(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)C=N1 RIXGYXRSHYBWDU-MHZLTWQESA-N 0.000 description 1
• FZPXRPMJRKWKNF-JTQLQIEISA-N (6s)-4-[(4-methoxyphenyl)methyl]-6-methylmorpholin-3-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)CO[C@@H](C)C1 FZPXRPMJRKWKNF-JTQLQIEISA-N 0.000 description 1
• BKMMTJMQCTUHRP-VKHMYHEASA-N (S)-2-aminopropan-1-ol Chemical compound C[C@H](N)CO BKMMTJMQCTUHRP-VKHMYHEASA-N 0.000 description 1
• JWQMKMSVOYQICF-OWOJBTEDSA-N (e)-1,3-dibromoprop-1-ene Chemical compound BrC\C=C\Br JWQMKMSVOYQICF-OWOJBTEDSA-N 0.000 description 1
• YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
• DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
• NEJAZTRECPSKQI-UHFFFAOYSA-N 1-(2-cyclohexylethyl)imidazole-4-carbaldehyde Chemical compound C1=NC(C=O)=CN1CCC1CCCCC1 NEJAZTRECPSKQI-UHFFFAOYSA-N 0.000 description 1
• JANNNSREBOLUIJ-UHFFFAOYSA-N 1-(2-phenylethyl)imidazole-4-carbaldehyde Chemical compound C1=NC(C=O)=CN1CCC1=CC=CC=C1 JANNNSREBOLUIJ-UHFFFAOYSA-N 0.000 description 1
• OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
• YFUDIBSZKPCLQH-UHFFFAOYSA-N 1-bromo-4-cyclohexyloxybenzene Chemical compound C1=CC(Br)=CC=C1OC1CCCCC1 YFUDIBSZKPCLQH-UHFFFAOYSA-N 0.000 description 1
• MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 1
• CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 1
• PESXKUUFXACUMT-UHFFFAOYSA-N 1-butylimidazole-4-carbaldehyde Chemical compound CCCCN1C=NC(C=O)=C1 PESXKUUFXACUMT-UHFFFAOYSA-N 0.000 description 1
• VLWJUYLXFWFDSW-UHFFFAOYSA-N 1-propylimidazole-4-carbaldehyde Chemical compound CCCN1C=NC(C=O)=C1 VLWJUYLXFWFDSW-UHFFFAOYSA-N 0.000 description 1
• YQYLLBSWWRWWAY-UHFFFAOYSA-N 1-tritylimidazole-4-carbaldehyde Chemical compound C1=NC(C=O)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 YQYLLBSWWRWWAY-UHFFFAOYSA-N 0.000 description 1
• XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 1
• 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
• AHHSAESBCYZCJK-UHFFFAOYSA-N 2-(1h-imidazol-5-ylmethyl)-4-[(4-methoxyphenyl)methyl]morpholin-3-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)C(CC=2N=CNC=2)OCC1 AHHSAESBCYZCJK-UHFFFAOYSA-N 0.000 description 1
• LVCATUGNENEDGZ-UHFFFAOYSA-N 2-(2-aminoethoxy)-3-(1-phenylimidazol-4-yl)propanoic acid Chemical compound C1=NC(CC(OCCN)C(O)=O)=CN1C1=CC=CC=C1 LVCATUGNENEDGZ-UHFFFAOYSA-N 0.000 description 1
• UOUJOOGMEXVWAB-UHFFFAOYSA-N 2-(2-aminoethoxy)-3-[1-(2-methylphenyl)imidazol-4-yl]propanoic acid;dihydrochloride Chemical compound Cl.Cl.CC1=CC=CC=C1N1C=C(CC(OCCN)C(O)=O)N=C1 UOUJOOGMEXVWAB-UHFFFAOYSA-N 0.000 description 1
• PDPOUENXYDAFNN-UHFFFAOYSA-N 2-(2-aminoethoxy)-3-[1-(3-phenoxyphenyl)imidazol-4-yl]propanoic acid;dihydrochloride Chemical compound Cl.Cl.C1=NC(CC(OCCN)C(O)=O)=CN1C1=CC=CC(OC=2C=CC=CC=2)=C1 PDPOUENXYDAFNN-UHFFFAOYSA-N 0.000 description 1
• QKMJEFSXGBGXIW-UHFFFAOYSA-N 2-(2-aminoethoxy)-3-[1-[2-[4-(4-ethylphenyl)phenyl]ethyl]imidazol-4-yl]propanoic acid Chemical compound C1=CC(CC)=CC=C1C(C=C1)=CC=C1CCN1C=C(CC(OCCN)C(O)=O)N=C1 QKMJEFSXGBGXIW-UHFFFAOYSA-N 0.000 description 1
• SCVLLFPGDGZBHW-UHFFFAOYSA-N 2-(2-aminoethoxy)-3-[1-[3-(2-phenylphenyl)propyl]imidazol-4-yl]propanoic acid;dihydrochloride Chemical compound Cl.Cl.C1=NC(CC(OCCN)C(O)=O)=CN1CCCC1=CC=CC=C1C1=CC=CC=C1 SCVLLFPGDGZBHW-UHFFFAOYSA-N 0.000 description 1
• QHRHJIAGVYXPCC-UHFFFAOYSA-N 2-(2-aminoethoxy)-3-[1-[3-(3-phenylphenyl)propyl]imidazol-4-yl]propanoic acid;dihydrochloride Chemical compound Cl.Cl.C1=NC(CC(OCCN)C(O)=O)=CN1CCCC1=CC=CC(C=2C=CC=CC=2)=C1 QHRHJIAGVYXPCC-UHFFFAOYSA-N 0.000 description 1
• YZIFGTPLPIGMAY-UHFFFAOYSA-N 2-(3-methoxyphenyl)-6-morpholin-4-yl-4,4-bis(trifluoromethyl)-1,3,5-oxadiazine Chemical compound COC1=CC=CC(C=2OC(=NC(N=2)(C(F)(F)F)C(F)(F)F)N2CCOCC2)=C1 YZIFGTPLPIGMAY-UHFFFAOYSA-N 0.000 description 1
• SVNRZNYAUYWNBY-UHFFFAOYSA-N 2-(4,4-dimethylcyclohexyl)ethanol Chemical compound CC1(C)CCC(CCO)CC1 SVNRZNYAUYWNBY-UHFFFAOYSA-N 0.000 description 1
• LLYNKHIQZYPMTJ-UHFFFAOYSA-N 2-(4-bromophenyl)ethyl methanesulfonate Chemical compound CS(=O)(=O)OCCC1=CC=C(Br)C=C1 LLYNKHIQZYPMTJ-UHFFFAOYSA-N 0.000 description 1
• BPQOUXUKYIOGOA-UHFFFAOYSA-N 2-[(1-butylimidazol-4-yl)-hydroxymethyl]-4-[(4-methoxyphenyl)methyl]morpholin-3-one Chemical compound CCCCN1C=NC(C(O)C2C(N(CC=3C=CC(OC)=CC=3)CCO2)=O)=C1 BPQOUXUKYIOGOA-UHFFFAOYSA-N 0.000 description 1
• PHIRDXCOPCIEPN-UHFFFAOYSA-N 2-[(1-butylimidazol-4-yl)methyl]-4-[(4-methoxyphenyl)methyl]morpholin-3-one Chemical compound CCCCN1C=NC(CC2C(N(CC=3C=CC(OC)=CC=3)CCO2)=O)=C1 PHIRDXCOPCIEPN-UHFFFAOYSA-N 0.000 description 1
• DNMSMROVRJXOOV-UHFFFAOYSA-N 2-[(1-butylimidazol-4-yl)methyl]morpholin-3-one Chemical compound CCCCN1C=NC(CC2C(NCCO2)=O)=C1 DNMSMROVRJXOOV-UHFFFAOYSA-N 0.000 description 1
• FCEBBEXDCZPDKN-UHFFFAOYSA-N 2-[(1-butylimidazol-4-yl)methylidene]-4-[(4-methoxyphenyl)methyl]morpholin-3-one Chemical compound CCCCN1C=NC(C=C2C(N(CC=3C=CC(OC)=CC=3)CCO2)=O)=C1 FCEBBEXDCZPDKN-UHFFFAOYSA-N 0.000 description 1
• ZBQCWTSWKQXRHQ-UHFFFAOYSA-N 2-[(1-naphthalen-2-ylimidazol-4-yl)methyl]morpholin-3-one Chemical compound O=C1NCCOC1CC1=CN(C=2C=C3C=CC=CC3=CC=2)C=N1 ZBQCWTSWKQXRHQ-UHFFFAOYSA-N 0.000 description 1
• UBLCRUHXSMDNQZ-UHFFFAOYSA-N 2-[(4-methoxyphenyl)methylamino]ethanol Chemical compound COC1=CC=C(CNCCO)C=C1 UBLCRUHXSMDNQZ-UHFFFAOYSA-N 0.000 description 1
• HYTHQFHZAAMXAV-UHFFFAOYSA-N 2-[[1-(2-cyclohexylethyl)imidazol-4-yl]methyl]morpholin-3-one Chemical compound O=C1NCCOC1CC(N=C1)=CN1CCC1CCCCC1 HYTHQFHZAAMXAV-UHFFFAOYSA-N 0.000 description 1
• KPPYFIXQRUQCNT-UHFFFAOYSA-N 2-[[1-(2-cyclohexylethyl)imidazol-4-yl]methylidene]-4-[(4-methoxyphenyl)methyl]morpholin-3-one Chemical compound C1=CC(OC)=CC=C1CN(CCO1)C(=O)C1=CC(N=C1)=CN1CCC1CCCCC1 KPPYFIXQRUQCNT-UHFFFAOYSA-N 0.000 description 1
• BQGXSKBJQAEOQV-UHFFFAOYSA-N 2-[[1-(2-phenylethyl)imidazol-4-yl]methyl]morpholin-3-one Chemical compound O=C1NCCOC1CC(N=C1)=CN1CCC1=CC=CC=C1 BQGXSKBJQAEOQV-UHFFFAOYSA-N 0.000 description 1
• NENAIPDHZZMSPP-UHFFFAOYSA-N 2-[[1-(3-bromoprop-2-enyl)imidazol-4-yl]methyl]-4-[(4-methoxyphenyl)methyl]morpholin-3-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)C(CC=2N=CN(CC=CBr)C=2)OCC1 NENAIPDHZZMSPP-UHFFFAOYSA-N 0.000 description 1
• HWIQGVHRWMGGAF-UHFFFAOYSA-N 2-[[1-(3-bromoprop-2-enyl)imidazol-4-yl]methyl]morpholin-3-one Chemical compound BrC=CCN1C=NC(CC2C(NCCO2)=O)=C1 HWIQGVHRWMGGAF-UHFFFAOYSA-N 0.000 description 1
• JCPATMAFXQCATQ-UHFFFAOYSA-N 2-[[1-(3-phenoxyphenyl)imidazol-4-yl]methyl]morpholin-3-one Chemical compound O=C1NCCOC1CC1=CN(C=2C=C(OC=3C=CC=CC=3)C=CC=2)C=N1 JCPATMAFXQCATQ-UHFFFAOYSA-N 0.000 description 1
• SXKUJXXFFUAPQW-UHFFFAOYSA-N 2-[[1-[2-(4-bromophenyl)ethyl]imidazol-4-yl]methyl]-4-[(4-methoxyphenyl)methyl]morpholin-3-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)C(CC=2N=CN(CCC=3C=CC(Br)=CC=3)C=2)OCC1 SXKUJXXFFUAPQW-UHFFFAOYSA-N 0.000 description 1
• LGLZFQUZWFPVCN-UHFFFAOYSA-N 2-[[1-[2-(4-bromophenyl)ethyl]imidazol-4-yl]methyl]morpholin-3-one Chemical compound C1=CC(Br)=CC=C1CCN1C=C(CC2C(NCCO2)=O)N=C1 LGLZFQUZWFPVCN-UHFFFAOYSA-N 0.000 description 1
• JDLBWEQRGWSGEH-UHFFFAOYSA-N 2-[[1-[2-[4-(4-ethylphenyl)phenyl]ethyl]imidazol-4-yl]methyl]morpholin-3-one Chemical compound C1=CC(CC)=CC=C1C(C=C1)=CC=C1CCN1C=C(CC2C(NCCO2)=O)N=C1 JDLBWEQRGWSGEH-UHFFFAOYSA-N 0.000 description 1
• JLELVBPCQIVFOB-UHFFFAOYSA-N 2-[[1-[3-(3,4-dichlorophenyl)phenyl]imidazol-4-yl]methyl]morpholin-3-one Chemical compound C1=C(Cl)C(Cl)=CC=C1C1=CC=CC(N2C=C(CC3C(NCCO3)=O)N=C2)=C1 JLELVBPCQIVFOB-UHFFFAOYSA-N 0.000 description 1
• KBINJBZXKKHGLK-UHFFFAOYSA-N 2-[[1-[3-(4-bromophenyl)prop-2-enyl]imidazol-4-yl]methyl]morpholin-3-one Chemical compound C1=CC(Br)=CC=C1C=CCN1C=C(CC2C(NCCO2)=O)N=C1 KBINJBZXKKHGLK-UHFFFAOYSA-N 0.000 description 1
• HTVQGVYZEFSKFK-UHFFFAOYSA-N 2-[[1-[3-(4-chlorophenyl)phenyl]imidazol-4-yl]methyl]morpholin-3-one Chemical compound C1=CC(Cl)=CC=C1C1=CC=CC(N2C=C(CC3C(NCCO3)=O)N=C2)=C1 HTVQGVYZEFSKFK-UHFFFAOYSA-N 0.000 description 1
• JGKOXYPHGCAFEJ-UHFFFAOYSA-N 2-[[1-[3-(4-phenylphenyl)prop-2-enyl]imidazol-4-yl]methyl]morpholin-3-one Chemical compound O=C1NCCOC1CC(N=C1)=CN1CC=CC1=CC=C(C=2C=CC=CC=2)C=C1 JGKOXYPHGCAFEJ-UHFFFAOYSA-N 0.000 description 1
• QBQRPZQVIBXHCI-UHFFFAOYSA-N 2-[[1-[3-(4-phenylphenyl)propyl]imidazol-4-yl]methyl]morpholin-3-one Chemical compound O=C1NCCOC1CC(N=C1)=CN1CCCC1=CC=C(C=2C=CC=CC=2)C=C1 QBQRPZQVIBXHCI-UHFFFAOYSA-N 0.000 description 1
• XUBPTTSLPYFJCC-UHFFFAOYSA-N 2-[hydroxy-(1-propylimidazol-4-yl)methyl]-4-[(4-methoxyphenyl)methyl]morpholin-3-one Chemical compound CCCN1C=NC(C(O)C2C(N(CC=3C=CC(OC)=CC=3)CCO2)=O)=C1 XUBPTTSLPYFJCC-UHFFFAOYSA-N 0.000 description 1
• XDFTZRAJODZJDJ-UHFFFAOYSA-N 2-[hydroxy-(1-propylimidazol-4-yl)methyl]-4-methylmorpholin-3-one Chemical compound CCCN1C=NC(C(O)C2C(N(C)CCO2)=O)=C1 XDFTZRAJODZJDJ-UHFFFAOYSA-N 0.000 description 1
• XDBCGXYVTYWDGW-UHFFFAOYSA-N 2-[hydroxy-(1-tritylimidazol-4-yl)methyl]-4-[(4-methoxyphenyl)methyl]morpholin-3-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)C(C(O)C=2N=CN(C=2)C(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)OCC1 XDBCGXYVTYWDGW-UHFFFAOYSA-N 0.000 description 1
• DKTIKSGAIXNLGB-UHFFFAOYSA-N 2-[hydroxy-[1-(2-phenylethyl)imidazol-4-yl]methyl]-4-[(4-methoxyphenyl)methyl]morpholin-3-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)C(C(O)C=2N=CN(CCC=3C=CC=CC=3)C=2)OCC1 DKTIKSGAIXNLGB-UHFFFAOYSA-N 0.000 description 1
• 125000005999 2-bromoethyl group Chemical group 0.000 description 1
• IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 1
• PWJXPRDSYLKFQZ-UHFFFAOYSA-N 2-hydroxy-2-(1h-imidazol-2-yl)acetic acid Chemical class OC(=O)C(O)C1=NC=CN1 PWJXPRDSYLKFQZ-UHFFFAOYSA-N 0.000 description 1
• 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
• LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
• WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
• ZRVRQSMNOOPMCY-JHJMLUEUSA-N 3-(1-propylimidazol-4-yl)-2-[(3r)-pyrrolidin-3-yl]oxypropanoic acid Chemical compound CCCN1C=NC(CC(O[C@H]2CNCC2)C(O)=O)=C1 ZRVRQSMNOOPMCY-JHJMLUEUSA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• IIWIBQFOUWSNJI-UHFFFAOYSA-N 3-cyclohexyl-3-methylbutan-1-ol Chemical compound OCCC(C)(C)C1CCCCC1 IIWIBQFOUWSNJI-UHFFFAOYSA-N 0.000 description 1
• JBIYSTLVHILJDJ-UHFFFAOYSA-N 4-(2-bromoethyl)-1,1-dimethylcyclohexane Chemical compound CC1(C)CCC(CCBr)CC1 JBIYSTLVHILJDJ-UHFFFAOYSA-N 0.000 description 1
• DSMVNFZDAQHPKR-UHFFFAOYSA-N 4-[(4-methoxyphenyl)methyl]-2-[(1-phenylimidazol-4-yl)methyl]morpholin-3-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)C(CC=2N=CN(C=2)C=2C=CC=CC=2)OCC1 DSMVNFZDAQHPKR-UHFFFAOYSA-N 0.000 description 1
• PWLUZWXTOHKJDB-UHFFFAOYSA-N 4-[(4-methoxyphenyl)methyl]-2-[(1-propylimidazol-4-yl)methylidene]morpholin-3-one Chemical compound CCCN1C=NC(C=C2C(N(CC=3C=CC(OC)=CC=3)CCO2)=O)=C1 PWLUZWXTOHKJDB-UHFFFAOYSA-N 0.000 description 1
• CKUYPEWSIGTLOD-UHFFFAOYSA-N 4-[(4-methoxyphenyl)methyl]-2-[(1-tritylimidazol-4-yl)methylidene]morpholin-3-one Chemical compound C1=CC(OC)=CC=C1CN(CCO1)C(=O)C1=CC1=CN(C(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)C=N1 CKUYPEWSIGTLOD-UHFFFAOYSA-N 0.000 description 1
• PNNVZZSYJCNJKO-UHFFFAOYSA-N 4-[(4-methoxyphenyl)methyl]-2-[[1-(2-methylphenyl)imidazol-4-yl]methyl]morpholin-3-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)C(CC=2N=CN(C=2)C=2C(=CC=CC=2)C)OCC1 PNNVZZSYJCNJKO-UHFFFAOYSA-N 0.000 description 1
• POSHOANDKJHEGJ-UHFFFAOYSA-N 4-[(4-methoxyphenyl)methyl]-2-[[1-(2-phenylethyl)imidazol-4-yl]methylidene]morpholin-3-one Chemical compound C1=CC(OC)=CC=C1CN(CCO1)C(=O)C1=CC(N=C1)=CN1CCC1=CC=CC=C1 POSHOANDKJHEGJ-UHFFFAOYSA-N 0.000 description 1
• LPCCMTBONRKJBL-UHFFFAOYSA-N 4-[(4-methoxyphenyl)methyl]-2-[[1-(3-phenoxyphenyl)imidazol-4-yl]methyl]morpholin-3-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)C(CC=2N=CN(C=2)C=2C=C(OC=3C=CC=CC=3)C=CC=2)OCC1 LPCCMTBONRKJBL-UHFFFAOYSA-N 0.000 description 1
• PMVWFIQQJAJAOM-UHFFFAOYSA-N 4-[(4-methoxyphenyl)methyl]morpholin-3-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)COCC1 PMVWFIQQJAJAOM-UHFFFAOYSA-N 0.000 description 1
• 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
• ICPTZQVAPWRXHP-UHFFFAOYSA-N 4-methyl-2-[(1-propylimidazol-4-yl)methyl]morpholin-3-one Chemical compound CCCN1C=NC(CC2C(N(C)CCO2)=O)=C1 ICPTZQVAPWRXHP-UHFFFAOYSA-N 0.000 description 1
• IZIMDENGABYBKK-UHFFFAOYSA-N 4-methyl-2-[(1-propylimidazol-4-yl)methylidene]morpholin-3-one Chemical compound CCCN1C=NC(C=C2C(N(C)CCO2)=O)=C1 IZIMDENGABYBKK-UHFFFAOYSA-N 0.000 description 1
• SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 201000005657 Antithrombin III deficiency Diseases 0.000 description 1
• 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
• 208000025978 Athletic injury Diseases 0.000 description 1
• 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
• 206010004053 Bacterial toxaemia Diseases 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• 101000946522 Bos taurus Carboxypeptidase B Proteins 0.000 description 1
• 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 102100035024 Carboxypeptidase B Human genes 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 206010053567 Coagulopathies Diseases 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 208000034656 Contusions Diseases 0.000 description 1
• 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
• 229920002785 Croscarmellose sodium Polymers 0.000 description 1
• XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
• RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
• 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
• LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
• 208000032928 Dyslipidaemia Diseases 0.000 description 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
• 238000004252 FT/ICR mass spectrometry Methods 0.000 description 1
• 108010014172 Factor V Proteins 0.000 description 1
• 229940122564 Factor X inhibitor Drugs 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
• 206010019280 Heart failures Diseases 0.000 description 1
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
• 108700017371 Heparin Cofactor II Deficiency Proteins 0.000 description 1
• 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
• 102000007625 Hirudins Human genes 0.000 description 1
• 108010007267 Hirudins Proteins 0.000 description 1
• 101000946524 Homo sapiens Carboxypeptidase B Proteins 0.000 description 1
• 101000946518 Homo sapiens Carboxypeptidase B2 Proteins 0.000 description 1
• 101000910843 Homo sapiens Carboxypeptidase N catalytic chain Proteins 0.000 description 1
• 206010048707 Homocystinaemia Diseases 0.000 description 1
• 206010020365 Homocystinuria Diseases 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
• 206010020608 Hypercoagulation Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 229930194542 Keto Natural products 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• 208000034693 Laceration Diseases 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• 208000017170 Lipid metabolism disease Diseases 0.000 description 1
• 239000012448 Lithium borohydride Substances 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 240000003183 Manihot esculenta Species 0.000 description 1
• 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
• OPKOKAMJFNKNAS-UHFFFAOYSA-N N-methylethanolamine Chemical compound CNCCO OPKOKAMJFNKNAS-UHFFFAOYSA-N 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• 206010029113 Neovascularisation Diseases 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• 244000018764 Nyssa sylvatica Species 0.000 description 1
• 235000003339 Nyssa sylvatica Nutrition 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
• ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 229920001214 Polysorbate 60 Polymers 0.000 description 1
• 239000004793 Polystyrene Substances 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 101800004937 Protein C Proteins 0.000 description 1
• 102000017975 Protein C Human genes 0.000 description 1
• 229940096437 Protein S Drugs 0.000 description 1
• 102000029301 Protein S Human genes 0.000 description 1
• 108010066124 Protein S Proteins 0.000 description 1
• 206010038563 Reocclusion Diseases 0.000 description 1
• 101800001700 Saposin-D Proteins 0.000 description 1
• 206010039580 Scar Diseases 0.000 description 1
• 229940124639 Selective inhibitor Drugs 0.000 description 1
• 208000004078 Snake Bites Diseases 0.000 description 1
• HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
• 239000004147 Sorbitan trioleate Substances 0.000 description 1
• PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 108010023197 Streptokinase Proteins 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 1
• 229940122388 Thrombin inhibitor Drugs 0.000 description 1
• 208000013222 Toxemia Diseases 0.000 description 1
• 208000003441 Transfusion reaction Diseases 0.000 description 1
• 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
• 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
• 208000024248 Vascular System injury Diseases 0.000 description 1
• 208000012339 Vascular injury Diseases 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• 240000008042 Zea mays Species 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
• WMJMABVHDMRMJA-UHFFFAOYSA-M [Cl-].[Mg+]C1CCCCC1 Chemical compound [Cl-].[Mg+]C1CCCCC1 WMJMABVHDMRMJA-UHFFFAOYSA-M 0.000 description 1
• PDWASPORWPXCHZ-IMIWJGOWSA-M [Li+].C1=NC(C[C@H](O[C@@H](CNC(=O)OC(C)(C)C)C)C([O-])=O)=CN1C(C=C1)=CC=C1OC1CCCCC1 Chemical compound [Li+].C1=NC(C[C@H](O[C@@H](CNC(=O)OC(C)(C)C)C)C([O-])=O)=CN1C(C=C1)=CC=C1OC1CCCCC1 PDWASPORWPXCHZ-IMIWJGOWSA-M 0.000 description 1
• 230000003187 abdominal effect Effects 0.000 description 1
• 229960001138 acetylsalicylic acid Drugs 0.000 description 1
• 208000017733 acquired polycythemia vera Diseases 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 230000000996 additive effect Effects 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 125000003342 alkenyl group Chemical group 0.000 description 1
• 230000029936 alkylation Effects 0.000 description 1
• 125000000304 alkynyl group Chemical group 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• 229960002684 aminocaproic acid Drugs 0.000 description 1
• IYIKLHRQXLHMJQ-UHFFFAOYSA-N amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 description 1
• 229960005260 amiodarone Drugs 0.000 description 1
• 230000003288 anthiarrhythmic effect Effects 0.000 description 1
• 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
• 230000001567 anti-fibrinolytic effect Effects 0.000 description 1
• 239000003416 antiarrhythmic agent Substances 0.000 description 1
• 229940127219 anticoagulant drug Drugs 0.000 description 1
• 229940030600 antihypertensive agent Drugs 0.000 description 1
• 239000002220 antihypertensive agent Substances 0.000 description 1
• 229940127218 antiplatelet drug Drugs 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 238000010936 aqueous wash Methods 0.000 description 1
• 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
• 150000001543 aryl boronic acids Chemical class 0.000 description 1
• 238000006254 arylation reaction Methods 0.000 description 1
• 125000002393 azetidinyl group Chemical group 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 229940077388 benzenesulfonate Drugs 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 235000010290 biphenyl Nutrition 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• KDPAWGWELVVRCH-UHFFFAOYSA-M bromoacetate Chemical compound [O-]C(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-M 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• 239000006227 byproduct Substances 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 229910000019 calcium carbonate Inorganic materials 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
• 125000004432 carbon atom Chemical group C* 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229910002092 carbon dioxide Inorganic materials 0.000 description 1
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 210000004027 cell Anatomy 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• XMPZTFVPEKAKFH-UHFFFAOYSA-P ceric ammonium nitrate Chemical compound [NH4+].[NH4+].[Ce+4].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O XMPZTFVPEKAKFH-UHFFFAOYSA-P 0.000 description 1
• 229940081733 cetearyl alcohol Drugs 0.000 description 1
• 229920001429 chelating resin Polymers 0.000 description 1
• 125000004775 chlorodifluoromethyl group Chemical group FC(F)(Cl)* 0.000 description 1
• IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 230000008576 chronic process Effects 0.000 description 1
• 230000004087 circulation Effects 0.000 description 1
• 208000019425 cirrhosis of liver Diseases 0.000 description 1
• 235000015165 citric acid Nutrition 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 238000002485 combustion reaction Methods 0.000 description 1
• 238000010668 complexation reaction Methods 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 230000009519 contusion Effects 0.000 description 1
• OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 208000026758 coronary atherosclerosis Diseases 0.000 description 1
• 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
• 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
• 238000009109 curative therapy Methods 0.000 description 1
• 229940097362 cyclodextrins Drugs 0.000 description 1
• 150000001934 cyclohexanes Chemical class 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 230000018044 dehydration Effects 0.000 description 1
• 238000006297 dehydration reaction Methods 0.000 description 1
• 239000008367 deionised water Substances 0.000 description 1
• 229910021641 deionized water Inorganic materials 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 239000007933 dermal patch Substances 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 235000019700 dicalcium phosphate Nutrition 0.000 description 1
• 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
• 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
• 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
• 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
• 229960005156 digoxin Drugs 0.000 description 1
• LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
• 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
• IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
• 238000007865 diluting Methods 0.000 description 1
• 125000005879 dioxolanyl group Chemical group 0.000 description 1
• IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
• 229960002768 dipyridamole Drugs 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
• 238000004821 distillation Methods 0.000 description 1
• 229940112141 dry powder inhaler Drugs 0.000 description 1
• 239000008157 edible vegetable oil Substances 0.000 description 1
• 230000002526 effect on cardiovascular system Effects 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 239000008387 emulsifying waxe Substances 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
• PUUMIKKRWRRGRC-UHFFFAOYSA-N ethyl 3-cyclohexyl-3-methylbutanoate Chemical compound CCOC(=O)CC(C)(C)C1CCCCC1 PUUMIKKRWRRGRC-UHFFFAOYSA-N 0.000 description 1
• UTXVCHVLDOLVPC-UHFFFAOYSA-N ethyl 3-methylbut-2-enoate Chemical compound CCOC(=O)C=C(C)C UTXVCHVLDOLVPC-UHFFFAOYSA-N 0.000 description 1
• 238000001704 evaporation Methods 0.000 description 1
• 230000008020 evaporation Effects 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 210000002744 extracellular matrix Anatomy 0.000 description 1
• 230000004761 fibrosis Effects 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 239000012467 final product Substances 0.000 description 1
• 235000019634 flavors Nutrition 0.000 description 1
• 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 1
• 229910052731 fluorine Inorganic materials 0.000 description 1
• 125000001153 fluoro group Chemical group F* 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 239000012362 glacial acetic acid Substances 0.000 description 1
• 229940050410 gluconate Drugs 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• 229940049654 glyceryl behenate Drugs 0.000 description 1
• 230000013595 glycosylation Effects 0.000 description 1
• 238000006206 glycosylation reaction Methods 0.000 description 1
• 238000005469 granulation Methods 0.000 description 1
• 230000003179 granulation Effects 0.000 description 1
• 230000005484 gravity Effects 0.000 description 1
• 230000026030 halogenation Effects 0.000 description 1
• 238000005658 halogenation reaction Methods 0.000 description 1
• 239000007902 hard capsule Substances 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 208000019622 heart disease Diseases 0.000 description 1
• 210000003709 heart valve Anatomy 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 229920000669 heparin Polymers 0.000 description 1
• 208000007084 heparin cofactor II deficiency Diseases 0.000 description 1
• 208000033666 hereditary antithrombin deficiency Diseases 0.000 description 1
• UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
• WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
• 229940006607 hirudin Drugs 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 230000003284 homeostatic effect Effects 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• 150000005828 hydrofluoroalkanes Chemical class 0.000 description 1
• 239000000017 hydrogel Substances 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• 150000001261 hydroxy acids Chemical class 0.000 description 1
• 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
• 230000003027 hypercoagulation Effects 0.000 description 1
• WUJUYHMGDPTLMG-UHFFFAOYSA-N imidazol-2-ylacetic acid Chemical class OC(=O)CC1=NC=CN1 WUJUYHMGDPTLMG-UHFFFAOYSA-N 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 208000000509 infertility Diseases 0.000 description 1
• 230000036512 infertility Effects 0.000 description 1
• 231100000535 infertility Toxicity 0.000 description 1
• 210000004969 inflammatory cell Anatomy 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 238000009434 installation Methods 0.000 description 1
• 208000003243 intestinal obstruction Diseases 0.000 description 1
• 230000009545 invasion Effects 0.000 description 1
• 125000002346 iodo group Chemical group I* 0.000 description 1
• 238000004255 ion exchange chromatography Methods 0.000 description 1
• 230000002427 irreversible effect Effects 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• 125000000468 ketone group Chemical group 0.000 description 1
• 208000017169 kidney disease Diseases 0.000 description 1
• 150000002596 lactones Chemical class 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 229940057995 liquid paraffin Drugs 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 201000005857 malignant hypertension Diseases 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
• 229910052753 mercury Inorganic materials 0.000 description 1
• 230000009401 metastasis Effects 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 239000002808 molecular sieve Substances 0.000 description 1
• 125000006682 monohaloalkyl group Chemical group 0.000 description 1
• 125000002757 morpholinyl group Chemical group 0.000 description 1
• 230000035772 mutation Effects 0.000 description 1
• PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
• FTNFEHXDETWERN-UHFFFAOYSA-N n-[bis(aziridin-1-yl)phosphoryl]-2,6-dimethyl-5-[(4-propan-2-yloxyphenyl)methyl]pyrimidin-4-amine Chemical compound C1=CC(OC(C)C)=CC=C1CC1=C(C)N=C(C)N=C1NP(=O)(N1CC1)N1CC1 FTNFEHXDETWERN-UHFFFAOYSA-N 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 125000004433 nitrogen atom Chemical group N* 0.000 description 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
• 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 230000000399 orthopedic effect Effects 0.000 description 1
• 125000001715 oxadiazolyl group Chemical group 0.000 description 1
• 125000002971 oxazolyl group Chemical group 0.000 description 1
• 125000000466 oxiranyl group Chemical group 0.000 description 1
• 229910052763 palladium Inorganic materials 0.000 description 1
• 238000002638 palliative care Methods 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 230000007310 pathophysiology Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 239000008194 pharmaceutical composition Substances 0.000 description 1
• 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
• UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 235000011007 phosphoric acid Nutrition 0.000 description 1
• 150000003016 phosphoric acids Chemical class 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• 125000003386 piperidinyl group Chemical group 0.000 description 1
• 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
• 238000000711 polarimetry Methods 0.000 description 1
• 208000037244 polycythemia vera Diseases 0.000 description 1
• 125000006684 polyhaloalkyl group Polymers 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
• 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
• 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
• 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
• 229940113124 polysorbate 60 Drugs 0.000 description 1
• 229920002223 polystyrene Polymers 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 230000009862 primary prevention Effects 0.000 description 1
• 102000004196 processed proteins & peptides Human genes 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 229960000856 protein c Drugs 0.000 description 1
• 235000018102 proteins Nutrition 0.000 description 1
• 102000004169 proteins and genes Human genes 0.000 description 1
• 108090000623 proteins and genes Proteins 0.000 description 1
• 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
• 208000002815 pulmonary hypertension Diseases 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• 125000002098 pyridazinyl group Chemical group 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 125000000714 pyrimidinyl group Chemical group 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 238000006268 reductive amination reaction Methods 0.000 description 1
• 238000007634 remodeling Methods 0.000 description 1
• 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 239000002151 riboflavin Substances 0.000 description 1
• 230000009863 secondary prevention Effects 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 150000004760 silicates Chemical class 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• 159000000000 sodium salts Chemical class 0.000 description 1
• 239000008109 sodium starch glycolate Substances 0.000 description 1
• 229940079832 sodium starch glycolate Drugs 0.000 description 1
• 229920003109 sodium starch glycolate Polymers 0.000 description 1
• 239000007901 soft capsule Substances 0.000 description 1
• 239000011877 solvent mixture Substances 0.000 description 1
• 239000001587 sorbitan monostearate Substances 0.000 description 1
• 235000011076 sorbitan monostearate Nutrition 0.000 description 1
• 229940035048 sorbitan monostearate Drugs 0.000 description 1
• 235000019337 sorbitan trioleate Nutrition 0.000 description 1
• 229960000391 sorbitan trioleate Drugs 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 230000006641 stabilisation Effects 0.000 description 1
• 238000011105 stabilization Methods 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 239000008174 sterile solution Substances 0.000 description 1
• 239000011550 stock solution Substances 0.000 description 1
• 229960005202 streptokinase Drugs 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 208000024891 symptom Diseases 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• NMLKJMWQOSEQQO-ZDUSSCGKSA-N tert-butyl (2s)-2-[[1-[(2-methylpropan-2-yl)oxycarbonyl]imidazol-4-yl]methyl]-3-oxomorpholine-4-carboxylate Chemical compound O=C1N(C(=O)OC(C)(C)C)CCO[C@H]1CC1=CN(C(=O)OC(C)(C)C)C=N1 NMLKJMWQOSEQQO-ZDUSSCGKSA-N 0.000 description 1
• BBWOHUXOXDXKQS-JPYJTQIMSA-N tert-butyl (2s,6r)-2-[[1-(4-cyclohexyloxyphenyl)imidazol-4-yl]methyl]-6-methyl-3-oxomorpholine-4-carboxylate Chemical compound O1[C@H](C)CN(C(=O)OC(C)(C)C)C(=O)[C@@H]1CC1=CN(C=2C=CC(OC3CCCCC3)=CC=2)C=N1 BBWOHUXOXDXKQS-JPYJTQIMSA-N 0.000 description 1
• MFXSUUDNGWXSSB-KRWDZBQOSA-N tert-butyl (3S)-3-[3-[(2-methylpropan-2-yl)oxy]-3-oxo-1-(1-propylimidazol-4-yl)prop-1-en-2-yl]oxypyrrolidine-1-carboxylate Chemical compound CCCN1C=NC(C=C(O[C@@H]2CN(CC2)C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)=C1 MFXSUUDNGWXSSB-KRWDZBQOSA-N 0.000 description 1
• QJRQDTHJTXVAPP-LLVKDONJSA-N tert-butyl (3r)-3-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethoxy]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)CO[C@@H]1CCN(C(=O)OC(C)(C)C)C1 QJRQDTHJTXVAPP-LLVKDONJSA-N 0.000 description 1
• APCBTRDHCDOPNY-SSDOTTSWSA-N tert-butyl (3r)-3-hydroxypyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC[C@@H](O)C1 APCBTRDHCDOPNY-SSDOTTSWSA-N 0.000 description 1
• NFXYWOHCUFXTNU-ZENAZSQFSA-N tert-butyl (3s)-3-[1-[(2-methylpropan-2-yl)oxy]-1-oxo-3-(1-propylimidazol-4-yl)propan-2-yl]oxypyrrolidine-1-carboxylate Chemical compound CCCN1C=NC(CC(O[C@@H]2CN(CC2)C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)=C1 NFXYWOHCUFXTNU-ZENAZSQFSA-N 0.000 description 1
• MOQGUYJWBDUVJU-ZLPCBKJTSA-N tert-butyl (3s)-3-[1-hydroxy-3-[(2-methylpropan-2-yl)oxy]-3-oxo-1-(1-propylimidazol-4-yl)propan-2-yl]oxypyrrolidine-1-carboxylate Chemical compound CCCN1C=NC(C(O)C(O[C@@H]2CN(CC2)C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)=C1 MOQGUYJWBDUVJU-ZLPCBKJTSA-N 0.000 description 1
• JRTJCAGLERFXBZ-UHFFFAOYSA-N tert-butyl 2-[2-(dimethylamino)ethoxy]-3-(1-propylimidazol-4-yl)prop-2-enoate Chemical compound CCCN1C=NC(C=C(OCCN(C)C)C(=O)OC(C)(C)C)=C1 JRTJCAGLERFXBZ-UHFFFAOYSA-N 0.000 description 1
• DCDUNOLIAFZIED-UHFFFAOYSA-N tert-butyl 2-[2-(dimethylamino)ethoxy]-3-(1-propylimidazol-4-yl)propanoate Chemical compound CCCN1C=NC(CC(OCCN(C)C)C(=O)OC(C)(C)C)=C1 DCDUNOLIAFZIED-UHFFFAOYSA-N 0.000 description 1
• PJIXPQWTTSWHME-UHFFFAOYSA-N tert-butyl 2-[2-(dimethylamino)ethoxy]-3-hydroxy-3-(1-propylimidazol-4-yl)propanoate Chemical compound CCCN1C=NC(C(O)C(OCCN(C)C)C(=O)OC(C)(C)C)=C1 PJIXPQWTTSWHME-UHFFFAOYSA-N 0.000 description 1
• SYUKNPFXTJSPSL-UHFFFAOYSA-N tert-butyl 2-[2-(dimethylamino)ethoxy]acetate Chemical compound CN(C)CCOCC(=O)OC(C)(C)C SYUKNPFXTJSPSL-UHFFFAOYSA-N 0.000 description 1
• 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 150000003512 tertiary amines Chemical class 0.000 description 1
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
• 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
• 230000001225 therapeutic effect Effects 0.000 description 1
• 125000001113 thiadiazolyl group Chemical group 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• 125000001166 thiolanyl group Chemical group 0.000 description 1
• 229960003766 thrombin (human) Drugs 0.000 description 1
• 239000003868 thrombin inhibitor Substances 0.000 description 1
• PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
• 229960005001 ticlopidine Drugs 0.000 description 1
• 210000001578 tight junction Anatomy 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 125000004306 triazinyl group Chemical group 0.000 description 1
• 125000001425 triazolyl group Chemical group 0.000 description 1
• 229940029284 trichlorofluoromethane Drugs 0.000 description 1
• 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
• UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
• JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
• NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 1
• 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• 230000007306 turnover Effects 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 229960005356 urokinase Drugs 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 229960005080 warfarin Drugs 0.000 description 1
• PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 239000003643 water by type Substances 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1